PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
PMV Pharmaceuticals has appointed Philip Herman as Chief Commercial Officer to spearhead commercial strategy and launch preparations for rezatapopt, its first-in-class p53 reactivator for platinum-resistant/refractory ovarian cancer. The company plans to submit a New Drug Application for accelerated approval of rezatapopt in the first quarter of 20…